SCHEMBL2473022

SCHEMBL2473022

COC(=O)C1CCC(Oc2cccnc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.49
CHRNA4 P43681 2/20 0.49
EPHX2 P34913 1/20 0.47
KDM4E B2RXH2 2/20 0.45
ABL1 P00519 1/20 0.43
GAA P10253 1/20 0.43
JAK1 P23458 1/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPT P10636 1/20 0.42
TNKS O95271 1/20 0.42
PARP1 P09874 1/20 0.42
PARP2 Q9UGN5 1/20 0.42
KMT2A Q03164 1/20 0.42
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTT P42858 1/20 0.41
SPR P35270 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473021 1.00 CHRNB2 (0.49) CHRNB2CHRNA4EPHX2KDM4EABL1
SCHEMBL21525584 0.84 CHRNB2 (0.52) CHRNB2CHRNA4EPHX2KDM4EABL1
SCHEMBL22849321 0.82 EPHX2 (0.43) EPHX2KDM4EALDH1A1MAPTKMT2A
SCHEMBL21997067 0.82 EPHX2 (0.43) EPHX2KDM4EALDH1A1MAPTKMT2A
SCHEMBL2474749 0.82 CHRNB2 (0.48) CHRNB2CHRNA4EPHX2KDM4EABL1
SCHEMBL2474746 0.82 CHRNB2 (0.48) CHRNB2CHRNA4EPHX2KDM4EABL1
SCHEMBL2469594 0.82 ALDH1A1 (0.49) EPHX2GAAALDH1A1MAPTSMN1; SMN2
SCHEMBL2469592 0.82 ALDH1A1 (0.49) EPHX2GAAALDH1A1MAPTSMN1; SMN2
SCHEMBL2473042 0.82 ALDH1A1 (0.49) EPHX2GAAALDH1A1MAPTSMN1; SMN2
SCHEMBL16845110 0.82 CHRNB2 (0.67) CHRNB2CHRNA4EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370441-B1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-09-11 EP disclosed
US-8461152-B2 Arylcyclohexylethers of dihydrotetraazabenzoazulenes HOFFMANN-LA ROCHE INC. (US) 2013-06-11 US disclosed
US-20120225865-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES SCHNIDER PATRICK (CH) 2012-09-06 US disclosed
US-8227458-B2 Arylcyclohexylethers of dihydrotetraazabenzoazulenes HOFFMANN-LA ROCHE INC. (US) 2012-07-24 US disclosed
EP-2370441-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-10-05 EP disclosed
WO-2010060836-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-03 WO disclosed
US-20100137286-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES HOFFMANN-LA ROCHE, INC. 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225865-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES AVPR1A, AVPR1B, AVPR2 CHRNB2 503/4885CHRNA4 392/4885EPHX2 3294/4885
US-20100137286-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES AVPR1A, AVPR1B, AVPR2 CHRNB2 503/4885CHRNA4 392/4885EPHX2 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.